PL3433238T3 - Środki o wysokim powinowactwie ukierunkowane na antygen błonowy specyficzny dla gruczołu krokowego do endoradioterapii raka gruczołu krokowego - Google Patents
Środki o wysokim powinowactwie ukierunkowane na antygen błonowy specyficzny dla gruczołu krokowego do endoradioterapii raka gruczołu krokowegoInfo
- Publication number
- PL3433238T3 PL3433238T3 PL17771028T PL17771028T PL3433238T3 PL 3433238 T3 PL3433238 T3 PL 3433238T3 PL 17771028 T PL17771028 T PL 17771028T PL 17771028 T PL17771028 T PL 17771028T PL 3433238 T3 PL3433238 T3 PL 3433238T3
- Authority
- PL
- Poland
- Prior art keywords
- prostate
- endoradiotherapy
- specific membrane
- membrane antigen
- affinity agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662311697P | 2016-03-22 | 2016-03-22 | |
| EP17771028.2A EP3433238B1 (en) | 2016-03-22 | 2017-03-22 | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
| PCT/US2017/023508 WO2017165473A1 (en) | 2016-03-22 | 2017-03-22 | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3433238T3 true PL3433238T3 (pl) | 2021-12-13 |
Family
ID=59899817
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17771028T PL3433238T3 (pl) | 2016-03-22 | 2017-03-22 | Środki o wysokim powinowactwie ukierunkowane na antygen błonowy specyficzny dla gruczołu krokowego do endoradioterapii raka gruczołu krokowego |
| PL21177643.0T PL3925952T3 (pl) | 2016-03-22 | 2017-03-22 | Środki o wysokim powinowactwie ukierunkowane na antygen błonowy swoisty dla gruczołu krokowego do endoradioterapii raka gruczołu krokowego |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21177643.0T PL3925952T3 (pl) | 2016-03-22 | 2017-03-22 | Środki o wysokim powinowactwie ukierunkowane na antygen błonowy swoisty dla gruczołu krokowego do endoradioterapii raka gruczołu krokowego |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US11458213B2 (pl) |
| EP (3) | EP3925952B1 (pl) |
| JP (3) | JP7073270B2 (pl) |
| KR (4) | KR102396307B1 (pl) |
| CN (3) | CN120172884A (pl) |
| AU (1) | AU2017238181B2 (pl) |
| BR (1) | BR112018069507A2 (pl) |
| CA (1) | CA3018709A1 (pl) |
| CL (1) | CL2018002683A1 (pl) |
| CY (1) | CY1124487T1 (pl) |
| DK (2) | DK3433238T3 (pl) |
| ES (2) | ES2972148T3 (pl) |
| FI (1) | FI3925952T3 (pl) |
| HR (2) | HRP20240215T1 (pl) |
| HU (2) | HUE055607T2 (pl) |
| LT (2) | LT3925952T (pl) |
| MX (1) | MX384823B (pl) |
| PH (1) | PH12018502048A1 (pl) |
| PL (2) | PL3433238T3 (pl) |
| PT (2) | PT3925952T (pl) |
| RS (2) | RS62274B1 (pl) |
| RU (2) | RU2749399C2 (pl) |
| SA (1) | SA518400103B1 (pl) |
| SI (2) | SI3925952T1 (pl) |
| TR (1) | TR201813644T1 (pl) |
| WO (1) | WO2017165473A1 (pl) |
| ZA (1) | ZA201806389B (pl) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX392700B (es) | 2016-08-10 | 2025-03-11 | Cancer Targeted Tech Llc | Inhibidores de antígeno de la membrana específico para la próstata (psma) quelados. |
| MX2019005742A (es) * | 2016-11-23 | 2019-09-13 | Cancer Targeted Tech Llc | Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina. |
| CN116474108A (zh) | 2016-12-14 | 2023-07-25 | 普渡研究基金会 | 成纤维细胞活化蛋白(fap)-靶向成像和治疗 |
| JP7373998B2 (ja) | 2017-05-02 | 2023-11-06 | コーネル・ユニバーシティー | 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬 |
| JP2020522506A (ja) * | 2017-05-30 | 2020-07-30 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 前立腺がんの内部放射線療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤 |
| EP3494998A1 (en) * | 2017-12-11 | 2019-06-12 | Technische Universität München | Glycosylated psma inhibitors for imaging and endoradiotherapy |
| PT4008359T (pt) * | 2017-12-11 | 2024-10-25 | Univ Muenchen Tech | Ligandos psma para imagiologia e endorradioterapia |
| EP3494999A1 (en) * | 2017-12-11 | 2019-06-12 | Technische Universität München | Psma ligands for imaging and endoradiotherapy |
| FI3498308T3 (fi) | 2017-12-13 | 2025-02-05 | Sciencons AS | Kompleksi, joka käsittää lyijy- tai toriumradionuklidiin sitoutunutta psma:han kohdentuvaa yhdistettä |
| KR20250021601A (ko) * | 2018-02-06 | 2025-02-13 | 우니베르시타트 하이델베르크 | Fap 억제제 |
| BR112020016040A2 (pt) * | 2018-02-06 | 2020-12-08 | The Johns Hopkins University | Ureia-poliaminocarboxilatos radiohalogenados que utilizam psma como alvo para radioterapia contra câncer |
| CA3094620C (en) * | 2018-03-30 | 2022-11-22 | Futurechem Co., Ltd. | Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer |
| CA3098492A1 (en) | 2018-04-27 | 2019-12-19 | University Of Iowa Research Foundation | Compositions for chelating metals at low temperatures |
| EP3856261A1 (en) * | 2018-09-28 | 2021-08-04 | Universität Heidelberg | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers |
| RU2697519C1 (ru) * | 2018-10-15 | 2019-08-15 | Общество с ограниченной ответственностью "Изварино Фарма" | Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом |
| KR102403970B1 (ko) * | 2018-12-27 | 2022-05-31 | (주)퓨쳐켐 | 카르복시산이 도입된 psma-표적 화합물 및 그의 용도 |
| RU2713151C1 (ru) * | 2019-07-02 | 2020-02-04 | Общество с ограниченной ответственностью "Изварино Фарма" | Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения |
| JP7608378B2 (ja) * | 2019-07-02 | 2025-01-06 | ノバルティス アーゲー | 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用 |
| EP3993837A1 (en) | 2019-07-02 | 2022-05-11 | Advanced Accelerator Applications (Italy) Srl | Prostate specific membrane antigen (psma) ligands and uses thereof |
| RU2730507C1 (ru) * | 2019-08-27 | 2020-08-24 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Соединение для диагностики опухолей, экспрессирующих псма, и композиция на его основе |
| JP2023523235A (ja) * | 2020-04-29 | 2023-06-02 | ノバルティス アーゲー | Ｐｓｍａ結合リガンドを放射標識するための方法及びそれらのキット |
| WO2022043557A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| WO2022043556A1 (en) | 2020-08-31 | 2022-03-03 | Novartis Ag | Stable radiopharmaceutical composition |
| US20230338587A1 (en) | 2020-08-31 | 2023-10-26 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| US20230406847A1 (en) | 2020-11-12 | 2023-12-21 | Abx Advanced Biochemical Compounds Gmbh | Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks |
| US20240010623A1 (en) | 2020-11-19 | 2024-01-11 | Novartis Ag | Synthesis of prostate specific membrane antigen (psma) ligands |
| MX2021005089A (es) * | 2021-04-30 | 2022-11-01 | Instituto Nac De Investigaciones Nucleares | Radiofarmacos basados en el acido ((r)-1-((6-hidrazinilnicotinoil) d-alanil)pirrolidin-2-il)boronico (hynic-ifap) para la deteccion de la sobreexpresion de la proteina de activacion de fibrolastos. |
| CA3222172A1 (en) * | 2021-06-17 | 2022-12-22 | Mayo Foundation For Medical Education And Research | Methods and materials for combining biologics with multiple chelators |
| KR20230050552A (ko) * | 2021-10-07 | 2023-04-17 | (주)퓨쳐켐 | 가돌리늄 화합물 및 이를 포함하는 전립선암의 진단 및 치료용 약학적 조성물 |
| US20250161502A1 (en) | 2022-02-09 | 2025-05-22 | Novartis Ag | Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent |
| EP4637843A2 (en) * | 2022-12-21 | 2025-10-29 | Mayo Foundation for Medical Education and Research | Methods and materials for combining biologics with multiple chelators |
| WO2025022285A2 (en) | 2023-07-21 | 2025-01-30 | Novartis Ag | Psma-targeting radioligand treatment regimen |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104774175B (zh) | 2007-06-26 | 2019-04-16 | 约翰·霍普金斯大学 | 标记的前列腺特异性膜抗原(psma)的抑制子、生物学评估及作为成像试剂的用途 |
| US9422234B2 (en) | 2007-11-30 | 2016-08-23 | The Johns Hopkins University | Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer |
| EP2373622A2 (en) | 2008-12-05 | 2011-10-12 | Molecular Insight Pharmaceuticals, Inc. | Ca-ix specific radiopharmaceuticals for the treatment and imaging of cancer |
| LT3964502T (lt) | 2009-03-19 | 2024-08-26 | The Johns Hopkins University | Junginiai nukreipti į psma ir jų panaudojimas |
| JP5843338B2 (ja) | 2011-08-05 | 2016-01-13 | モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド | 放射標識された前立腺特異的膜抗原阻害剤 |
| EP3524277B1 (en) * | 2011-11-30 | 2023-03-08 | The Johns Hopkins University | Psma-targeting compound and uses thereof |
| JP6468602B2 (ja) * | 2013-01-14 | 2019-02-13 | モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド | トリアジン系放射性医薬品及び放射線造影剤 |
| PE20211760A1 (es) * | 2013-10-18 | 2021-09-07 | Deutsches Krebsforsch | Inhibidores marcados de antigeno prostatico especifico de membrana (psma) que comprenden grupos carboxilicos y una region de enlazador modificada, agentes formadores de imagenes y agentes farmaceuticos que los comprenden |
| EP2862857A1 (en) * | 2013-10-18 | 2015-04-22 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| AU2015256002B2 (en) * | 2014-05-06 | 2020-01-02 | Northwestern University | Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy |
| ES2912753T3 (es) | 2014-08-24 | 2022-05-27 | Max Planck Gesellschaft Zur Foerderung Der Wss | Método para la producción de ésteres activos marcados con 18F y su aplicación ejemplificada por la preparación de un marcador de PET específico de PSMA |
| WO2016065435A2 (en) * | 2014-10-30 | 2016-05-06 | Katholieke Universiteit Leuven | Methods for low temperature fluorine-18 radiolabeling of biomolecules |
| US11520472B2 (en) * | 2015-09-24 | 2022-12-06 | Mitutoyo Corporation | Inspection program editing environment including integrated alignment program planning and editing features |
| US10688200B2 (en) * | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
-
2017
- 2017-03-22 PL PL17771028T patent/PL3433238T3/pl unknown
- 2017-03-22 HR HRP20240215TT patent/HRP20240215T1/hr unknown
- 2017-03-22 SI SI201731477T patent/SI3925952T1/sl unknown
- 2017-03-22 KR KR1020187030310A patent/KR102396307B1/ko active Active
- 2017-03-22 DK DK17771028.2T patent/DK3433238T3/da active
- 2017-03-22 EP EP21177643.0A patent/EP3925952B1/en active Active
- 2017-03-22 BR BR112018069507A patent/BR112018069507A2/pt unknown
- 2017-03-22 LT LTEP21177643.0T patent/LT3925952T/lt unknown
- 2017-03-22 CN CN202510305793.6A patent/CN120172884A/zh active Pending
- 2017-03-22 PT PT211776430T patent/PT3925952T/pt unknown
- 2017-03-22 SI SI201730908T patent/SI3433238T1/sl unknown
- 2017-03-22 JP JP2018549808A patent/JP7073270B2/ja active Active
- 2017-03-22 KR KR1020227015010A patent/KR20220063298A/ko not_active Ceased
- 2017-03-22 KR KR1020257012794A patent/KR20250057132A/ko active Pending
- 2017-03-22 ES ES21177643T patent/ES2972148T3/es active Active
- 2017-03-22 LT LTEPPCT/US2017/023508T patent/LT3433238T/lt unknown
- 2017-03-22 PL PL21177643.0T patent/PL3925952T3/pl unknown
- 2017-03-22 WO PCT/US2017/023508 patent/WO2017165473A1/en not_active Ceased
- 2017-03-22 CN CN201780031580.2A patent/CN109311827B/zh active Active
- 2017-03-22 RU RU2018133693A patent/RU2749399C2/ru active
- 2017-03-22 RS RS20211071A patent/RS62274B1/sr unknown
- 2017-03-22 HU HUE17771028A patent/HUE055607T2/hu unknown
- 2017-03-22 ES ES17771028T patent/ES2877572T3/es active Active
- 2017-03-22 FI FIEP21177643.0T patent/FI3925952T3/fi active
- 2017-03-22 AU AU2017238181A patent/AU2017238181B2/en active Active
- 2017-03-22 CA CA3018709A patent/CA3018709A1/en active Pending
- 2017-03-22 PT PT177710282T patent/PT3433238T/pt unknown
- 2017-03-22 EP EP24153551.7A patent/EP4385981A1/en active Pending
- 2017-03-22 EP EP17771028.2A patent/EP3433238B1/en active Active
- 2017-03-22 KR KR1020237034341A patent/KR20230147751A/ko not_active Ceased
- 2017-03-22 HU HUE21177643A patent/HUE065327T2/hu unknown
- 2017-03-22 CN CN202210306552.XA patent/CN114716387B/zh active Active
- 2017-03-22 TR TR2018/13644A patent/TR201813644T1/tr unknown
- 2017-03-22 DK DK21177643.0T patent/DK3925952T3/da active
- 2017-03-22 US US16/087,395 patent/US11458213B2/en active Active
- 2017-03-22 RS RS20240205A patent/RS65188B1/sr unknown
- 2017-03-22 HR HRP20211386TT patent/HRP20211386T1/hr unknown
- 2017-03-22 RU RU2021115958A patent/RU2021115958A/ru unknown
- 2017-03-22 MX MX2018011519A patent/MX384823B/es unknown
-
2018
- 2018-09-21 CL CL2018002683A patent/CL2018002683A1/es unknown
- 2018-09-24 PH PH12018502048A patent/PH12018502048A1/en unknown
- 2018-09-25 ZA ZA2018/06389A patent/ZA201806389B/en unknown
- 2018-09-25 SA SA518400103A patent/SA518400103B1/ar unknown
-
2021
- 2021-09-13 CY CY20211100803T patent/CY1124487T1/el unknown
-
2022
- 2022-05-11 JP JP2022077992A patent/JP2022116028A/ja active Pending
- 2022-08-22 US US17/892,203 patent/US20230015736A1/en not_active Abandoned
-
2024
- 2024-01-11 JP JP2024002743A patent/JP2024050608A/ja active Pending
- 2024-12-13 US US18/979,841 patent/US20250195700A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE055607T2 (hu) | Prosztata-fajlagos membrán antigénhez célzott nagy affinitású szerek prosztatarák endoradioterápiájához | |
| EP3630733A4 (en) | HIGH AFFINITY AGENTS TARGETING A PROSTATE-SPECIFIC MEMBRANARY ANTIGEN FOR ENDORADIOTHERAPY IN PROSTATE CANCER | |
| IL266847B (en) | Cancer treatment methods that include tigit binding agents | |
| IL264674B1 (en) | Antibodies to siglec7 for cancer treatment | |
| SG10201913631TA (en) | Rna for cancer therapy | |
| PL3580211T3 (pl) | 2-heteroarylo-3-okso-2,3-dihydropirydazyno-4-karboksyamidy do leczenia nowotworu | |
| ZA201801024B (en) | 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer | |
| IL265697A (en) | Prostate cancer treatment | |
| IL264443A (en) | Methods of treating prostate cancer | |
| EP3271401A4 (en) | Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens | |
| PT3622953T (pt) | Tratamento combinado do cancro | |
| IL262342A (en) | Cancer treatment methods | |
| EP3223860A4 (en) | Methods of treating cancer by targeting tumor-associated macrophages | |
| IL263835A (en) | Exosome-guided treatment of cancer | |
| DK3344287T3 (da) | Anti-survivin-antistoffer til cancerterapi | |
| HK1259764A1 (en) | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer | |
| HK40028154A (en) | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer | |
| PT3356385T (pt) | Inibidores etiquetados com 18f de antigénio de membrana específico de próstata (psma) e utilização dos mesmos como agentes de imagiologia para o cancro da próstata | |
| GB201622214D0 (en) | treatment of cancer | |
| GB201604621D0 (en) | Treatment of cancer | |
| GB201604293D0 (en) | Treatment of cancer |